Innate Pharma Reports Reduced Net Loss for H1, Announces 30% Workforce Reduction, Shares Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2025
0mins
Should l Buy IPHA?
Source: NASDAQ.COM
Financial Performance: Innate Pharma reported a narrower first-half net loss of 21.34 million euros, down from 24.76 million euros the previous year, despite a decline in revenue to 4.86 million euros from 12.35 million euros.
Strategic Changes: The company plans to focus on preclinical research and development, streamline its organization with a 30% staff reduction, and expects to complete these changes by the first half of 2026.
Leadership Update: COO Yannis Morel will take on the additional role of Chief Scientific Officer following the departure of CSO Eric Vivier, who is returning to academia.
Clinical Trial Outlook: Innate Pharma anticipates a high-level read-out in the second half of 2026 for the Monalizumab Phase 3 PACIFIC-9 trial, which is partnered with AstraZeneca for treating Stage III non-small cell lung cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IPHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IPHA
Wall Street analysts forecast IPHA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.660
Low
5.00
Averages
6.50
High
8.00
Current: 1.660
Low
5.00
Averages
6.50
High
8.00
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Innate Pharma Reports Share and Voting Rights Data for 2025
- Total Shares Disclosure: As of December 31, 2025, Innate Pharma reports a total of 93,719,323 ordinary shares, along with 6,324 preferred shares from 2016 and 7,581 from 2017, indicating stability in its capital structure.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency regarding shareholder rights, which helps maintain investor confidence.
- Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's commitment to compliance, which enhances its credibility among investors.
- Market Transparency Enhancement: By regularly releasing share and voting rights data, Innate Pharma improves market transparency, facilitating investor understanding of its governance structure, potentially attracting more investor interest.
See More
Innate Pharma Releases Share and Voting Rights Data as of December 18, 2025
- Total Shares Disclosure: As of December 18, 2025, Innate Pharma has 92,197,823 ordinary shares outstanding, indicating stability in its capital structure, which may enhance investor confidence.
- Preferred Shares Information: The company also holds 6,324 Preferred Shares from 2016 and 7,581 from 2017, reflecting its capital diversity that could attract various types of investors.
- Voting Rights Overview: The total theoretical voting rights stand at 92,962,943, with exercisable rights at 92,944,368, showcasing transparency in corporate governance that may boost shareholder engagement.
- Biotech Development Focus: Innate Pharma is dedicated to developing immunotherapies for cancer, advancing multiple potential first-in-class assets, demonstrating its strategic positioning in high unmet medical needs in the healthcare sector.
See More
Innate Pharma Releases 2026 Financial Calendar
- Financial Calendar Release: Innate Pharma announced that it will release its 2026 financial reports before market opens, ensuring timely access to key information for investors, thereby enhancing transparency and trust.
- Information Access Channels: The company will provide all financial statements and corporate presentations on the investors section of its website, facilitating easy access for investors and analysts to the latest developments, which increases market attention towards the company.
- R&D Focus: Innate Pharma is dedicated to developing immunotherapies for cancer patients, particularly innovative drugs like Nectin-4 ADC and anti-KIR3DL2 antibodies, aimed at addressing high unmet medical needs and driving long-term growth for the company.
- Partnerships: The company has established collaborations with leading biopharmaceutical firms such as Sanofi and AstraZeneca, leveraging its expertise in immuno-oncology to further drive innovation and enhance market competitiveness.
See More
Innate Pharma Releases 2026 Financial Calendar with Key Dates
- Financial Reporting Schedule: Innate Pharma has announced its 2026 financial calendar, with the publication of 2025 financial statements set for March 26, 2026, ensuring timely access to key information for investors to support their decision-making.
- Quarterly Performance Releases: The revenue and cash position for Q1 2026 will be published on May 13, demonstrating the company's commitment to financial transparency, which may enhance investor confidence.
- Shareholder Meeting Date: The company plans to hold its Annual General Meeting on May 21, 2026, providing shareholders with an opportunity to engage in corporate governance and fostering communication between shareholders and management.
- Mid-Year Financial Update: The half-year financial statements will be released on September 17, 2026, further enhancing the company's transparency to the market and potentially attracting interest from prospective investors regarding its long-term growth potential.
See More
Innate Pharma Releases Share and Voting Rights Data as of November 27, 2025
- Total Shares Disclosure: As of November 27, 2025, Innate Pharma reports 92,196,523 ordinary shares outstanding, indicating a stable capital structure that enhances investor confidence in the company's long-term growth prospects.
- Voting Rights Information: The total theoretical voting rights stand at 92,962,943, with exercisable voting rights at 92,944,368, ensuring shareholder participation in governance and reflecting the company's commitment to transparency.
- Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's rigorous approach to compliance, which helps build market trust.
- Market Transparency Enhancement: By regularly releasing share and voting rights information, Innate Pharma not only boosts market transparency but also potentially attracts more investor interest in its innovative biotech products.
See More
Innate Pharma Releases Share and Voting Rights Data as of November 27, 2025
- Total Shares Disclosure: As of November 27, 2025, Innate Pharma has 92,196,523 ordinary shares outstanding, indicating a stable capital structure that enhances investor confidence in the company's long-term growth prospects.
- Voting Rights Information: The total theoretical voting rights amount to 92,962,943, with exercisable voting rights at 92,944,368, ensuring shareholder participation in corporate decisions and reflecting the company's commitment to transparency.
- Preferred Shares Status: The company holds 6,334 Preferred Shares from 2016 and 7,581 from 2017, indicating a diverse capital structure that may attract various types of investors.
- Compliance Statement: This disclosure aligns with the requirements of the French stock market regulator, showcasing Innate Pharma's commitment to compliance and transparency, which helps to enhance market trust.
See More
Innate Pharma Reports Share and Voting Rights Data for 2025
- Total Shares Disclosure: As of December 31, 2025, Innate Pharma reports a total of 93,719,323 ordinary shares, along with 6,324 preferred shares from 2016 and 7,581 from 2017, indicating stability in its capital structure.
- Voting Rights Information: The company has a total of 94,484,443 theoretical voting rights and 94,465,868 exercisable voting rights, ensuring transparency regarding shareholder rights, which helps maintain investor confidence.
- Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's commitment to compliance, which enhances its credibility among investors.
- Market Transparency Enhancement: By regularly releasing share and voting rights data, Innate Pharma improves market transparency, facilitating investor understanding of its governance structure, potentially attracting more investor interest.
See More
Innate Pharma Releases Share and Voting Rights Data as of December 18, 2025
- Total Shares Disclosure: As of December 18, 2025, Innate Pharma has 92,197,823 ordinary shares outstanding, indicating stability in its capital structure, which may enhance investor confidence.
- Preferred Shares Information: The company also holds 6,324 Preferred Shares from 2016 and 7,581 from 2017, reflecting its capital diversity that could attract various types of investors.
- Voting Rights Overview: The total theoretical voting rights stand at 92,962,943, with exercisable rights at 92,944,368, showcasing transparency in corporate governance that may boost shareholder engagement.
- Biotech Development Focus: Innate Pharma is dedicated to developing immunotherapies for cancer, advancing multiple potential first-in-class assets, demonstrating its strategic positioning in high unmet medical needs in the healthcare sector.
See More
Innate Pharma Releases 2026 Financial Calendar
- Financial Calendar Release: Innate Pharma announced that it will release its 2026 financial reports before market opens, ensuring timely access to key information for investors, thereby enhancing transparency and trust.
- Information Access Channels: The company will provide all financial statements and corporate presentations on the investors section of its website, facilitating easy access for investors and analysts to the latest developments, which increases market attention towards the company.
- R&D Focus: Innate Pharma is dedicated to developing immunotherapies for cancer patients, particularly innovative drugs like Nectin-4 ADC and anti-KIR3DL2 antibodies, aimed at addressing high unmet medical needs and driving long-term growth for the company.
- Partnerships: The company has established collaborations with leading biopharmaceutical firms such as Sanofi and AstraZeneca, leveraging its expertise in immuno-oncology to further drive innovation and enhance market competitiveness.
See More
Innate Pharma Releases 2026 Financial Calendar with Key Dates
- Financial Reporting Schedule: Innate Pharma has announced its 2026 financial calendar, with the publication of 2025 financial statements set for March 26, 2026, ensuring timely access to key information for investors to support their decision-making.
- Quarterly Performance Releases: The revenue and cash position for Q1 2026 will be published on May 13, demonstrating the company's commitment to financial transparency, which may enhance investor confidence.
- Shareholder Meeting Date: The company plans to hold its Annual General Meeting on May 21, 2026, providing shareholders with an opportunity to engage in corporate governance and fostering communication between shareholders and management.
- Mid-Year Financial Update: The half-year financial statements will be released on September 17, 2026, further enhancing the company's transparency to the market and potentially attracting interest from prospective investors regarding its long-term growth potential.
See More
Innate Pharma Releases Share and Voting Rights Data as of November 27, 2025
- Total Shares Disclosure: As of November 27, 2025, Innate Pharma reports 92,196,523 ordinary shares outstanding, indicating a stable capital structure that enhances investor confidence in the company's long-term growth prospects.
- Voting Rights Information: The total theoretical voting rights stand at 92,962,943, with exercisable voting rights at 92,944,368, ensuring shareholder participation in governance and reflecting the company's commitment to transparency.
- Compliance Adherence: This disclosure aligns with the French Commercial Code and AMF regulations, demonstrating Innate Pharma's rigorous approach to compliance, which helps build market trust.
- Market Transparency Enhancement: By regularly releasing share and voting rights information, Innate Pharma not only boosts market transparency but also potentially attracts more investor interest in its innovative biotech products.
See More
Innate Pharma Releases Share and Voting Rights Data as of November 27, 2025
- Total Shares Disclosure: As of November 27, 2025, Innate Pharma has 92,196,523 ordinary shares outstanding, indicating a stable capital structure that enhances investor confidence in the company's long-term growth prospects.
- Voting Rights Information: The total theoretical voting rights amount to 92,962,943, with exercisable voting rights at 92,944,368, ensuring shareholder participation in corporate decisions and reflecting the company's commitment to transparency.
- Preferred Shares Status: The company holds 6,334 Preferred Shares from 2016 and 7,581 from 2017, indicating a diverse capital structure that may attract various types of investors.
- Compliance Statement: This disclosure aligns with the requirements of the French stock market regulator, showcasing Innate Pharma's commitment to compliance and transparency, which helps to enhance market trust.
See More
